Glycyrrhizin

Glycyrrhizin

SCHEMBL17880405

CC1(C)[C@@H](OC2OC(C(=O)O)C(O)C(O)C2OC2OC(C(=O)O)C(O)C(O)C2O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 12/20 1.00
HSD11B2 P80365 11/20 1.00
SLCO1B3 Q9NPD5 2/20 1.00
SLCO1B1 Q9Y6L6 2/20 1.00
HMGB1 P09429 1/20 1.00
LMNA P02545 2/20 0.71
CES2 O00748 3/20 0.65
CES1 P23141 3/20 0.65
HSD17B1 P14061 1/20 0.65
HSD17B2 P37059 1/20 0.65
PTPN1 P18031 4/20 0.63
CYP3A4 P08684 2/20 0.63
MAPT P10636 2/20 0.63
MEN1 O00255 1/20 0.63
AKR1B10 O60218 1/20 0.63
ALOX5 P09917 1/20 0.63
PRKCH P24723 1/20 0.63
PTPN6 P29350 1/20 0.63
KMT2A Q03164 1/20 0.63
PTPN11 Q06124 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycyrrhizin SCHEMBL15833919 1.00 HSD11B1 (1.00) HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1
Glycyrrhizin SCHEMBL7688850 1.00 HSD11B1 (1.00) HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1
Glycyrrhizin SCHEMBL21424347 1.00 HSD11B1 (1.00) HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1
Glycyrrhizin SCHEMBL24626512 1.00 HSD11B1 (1.00) HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1
Glycyrrhizin SCHEMBL11007323 1.00 HSD11B1 (1.00) HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1
Glycyrrhizin SCHEMBL23309804 1.00 HSD11B1 (1.00) HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1
Glycyrrhizin SCHEMBL13294344 1.00 HSD11B1 (1.00) HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1
Glycyrrhizin SCHEMBL23747025 1.00 HSD11B1 (1.00) HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1
Glycyrrhizin SCHEMBL22200125 1.00 HSD11B1 (1.00) HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1
Glycyrrhizin SCHEMBL14514292 1.00 HSD11B1 (1.00) HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364173-A1 SYNERGISTIC HERBAL COMPOSITIONS FOR IMMUNITY, COLD AND COUGH LAILA NUTRA PRIVATE LIMITED (IN) 2023-11-16 US disclosed
US-20230181611-A1 REELIN/VEGF-C PRODUCTION/ACTIVATION PROMOTER AND SKIN EXTERNAL COMPOSITION USING THE SAME AMOREPACIFIC CORPORATION (KR) 2023-06-15 US disclosed
US-11647774-B2 Substance mixtures SYMRISE AG (DE) 2023-05-16 US disclosed
WO-2022064525-A1 \"SYNERGISTIC HERBAL COMPOSITIONS FOR IMMUNITY, COLD AND COUGH\ LAILA NUTRACEUTICALS (IN) 2022-03-31 WO disclosed
US-11135184-B2 Formulations for epidermal repair CLARIDEI LABORATORIES, INC. (US) 2021-10-05 US disclosed
US-10653173-B2 Method for masking unpleasant taste ANALYTICON DISCOVERY GMBH (DE) 2020-05-19 US disclosed
US-10421776-B2 Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide LEUKOCARE AG (DE) 2019-09-24 US disclosed
US-9629795-B2 Substance mixtures SYMRISE AG (DE) 2017-04-25 US disclosed
US-20160184298-A1 INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) NAT DEFENSE MEDICAL CT (TW) 2016-06-30 US disclosed
US-20160184298-A1 INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) NAT DEFENSE MEDICAL CT (TW) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10653173-B2 Method for masking unpleasant taste MANBA, TAS1R1, BDKRB1 HSD11B1 182/4885HSD11B2 222/4885SLCO1B3 1139/4885
US-20160184298-A1 INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) UGT2B7, UGT2B17, UGT1A10 HSD11B1 85/4885HSD11B2 99/4885SLCO1B3 126/4885
US-20230181611-A1 REELIN/VEGF-C PRODUCTION/ACTIVATION PROMOTER AND SKIN EXTERNAL COMPOSITION USING THE SAME VEGFA, KDR, EDF1 HSD11B1 980/4885HSD11B2 1185/4885SLCO1B3 4559/4885
US-10421776-B2 Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide IAPP, PCBP1, HSPA5 HSD11B1 3501/4885HSD11B2 3454/4885SLCO1B3 3532/4885
US-20230364173-A1 SYNERGISTIC HERBAL COMPOSITIONS FOR IMMUNITY, COLD AND COUGH IL5, CHIA, SLC30A6 HSD11B1 404/4885HSD11B2 282/4885SLCO1B3 1741/4885
US-11135184-B2 Formulations for epidermal repair KRT18, CUTA, DSG1 HSD11B1 3959/4885HSD11B2 3934/4885SLCO1B3 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.